WebTwo randomized controlled trials recently demonstrated an overall survival benefit with triplet therapy (androgen receptor axis-targeted agent [ARAT] + docetaxel + androgen deprivation therapy [ADT]) over doublet therapy (docetaxel + ADT) in metastatic hormone-sensitive prostate cancer (mHSPC), broadening the treatment options. WebThe Hormone Health Network (HHN), our public education arm, has continued to embody these principles by creating timely, accurate, relevant information that has helped …
The Endocrine Society and Hormone Health Network Launch First …
WebWe are a global community 18,000 strong energized by the promise of unraveling the mysteries of hormone disorders to care for patients and cure disease. We are devoted to advancing hormone research, excellence in … WebOur Endocrine Library features educational resources covering the diagnosis, symptoms, risk factors, treatments and therapies for hormone-related diseases and conditions. … death bowel
Triplet or Doublet Therapy in Metastatic Hormone-sensitive
Web10 mei 2024 · Men — When a high blood prolactin concentration interferes with the function of the testicles, the production of testosterone (the main male sex hormone), and sperm … Web14 jan. 2024 · Hormone Health Network (from the Endocrine Society). Hyperprolactinemia. Last Updated April 2024. Accessed December 15, 2024. The Mayo Clinic. Prolactinoma. … WebWHN is a registered 501(c)3 not-for-profit corporation to promote, advocate, and advance women’s wellbeing and longevity through clinical research and education about the … generator v bucks no verification